Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 13/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6242863 | 0.96 | GRIA4 (0.47) | GRIA4GRIA2MMP2MMP13HCRTR2 | |
| SCHEMBL26144760 | 0.88 | GRIA4 (0.42) | GRIA4GRIA2HCRTR2KCNH2 | |
| SCHEMBL12018129 | 0.78 | MMP2 (0.43) | MMP2MMP13HCRTR2 | |
| SCHEMBL12017976 | 0.78 | MMP2 (0.43) | MMP2MMP13HCRTR2 | |
| SCHEMBL23260491 | 0.74 | MMP2 (0.43) | MMP2MMP13 | |
| SCHEMBL12017977 | 0.74 | MMP2 (0.40) | MMP2MMP13HCRTR2 | |
| SCHEMBL12017953 | 0.74 | MMP2 (0.40) | MMP2MMP13HCRTR2 | |
| SCHEMBL12017966 | 0.74 | MMP2 (0.40) | MMP2MMP13HCRTR2 | |
| SCHEMBL5376182 | 0.74 | MMP2 (0.40) | MMP2MMP13HCRTR2 | |
| SCHEMBL18234121 | 0.73 | CA12 (0.46) | GRIA4GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395550-B1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6900353-B2 | Cyclopentyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | CANTELL BUDDY EUGENE (US) | 2004-08-12 | — | — | US | disclosed |
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | CANTRELL BUDDY EUGENE (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1395550-A1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1334087-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002098847-A1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002032858-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | GRIN2A, GRIN1, GRIK5 | GRIA4 15/4885GRIA2 13/4885MMP2 4819/4885 |
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | GRIN2B, GRIN2A, GRIN1 | GRIA4 14/4885GRIA2 7/4885MMP2 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.